RxDoctor Payments Data

Messina Michalsky

Psychiatric/Mental Health · Billings, MTNPI 1568867588

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $527 of the $626 with a category attached, or 84.2%. 7 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 45.2% of the total.

$626in general payments, 2019–2025

Across 27 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$283
  • Teva Pharmaceuticals USA, Inc.$137
  • AbbVie$83
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • Supernus Pharmaceuticals, Inc.$31
  • Sunovion Pharmaceuticals Inc.$18
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$52784%
  • Education$9916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$626 in reported general payments places this provider in the 80th percentile of 142 psychiatric/mental health providers in Montana.

See all psychiatric/mental health providers in Montana

Medicare billing

Part B allowed, 2024
$20,855
Medicare patients
22
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate15$45,929
RexultiBrexpiprazole18$27,345
VyvanseLisdexamfetamine Dimesylate23$8,509
Aripiprazole37$1,946
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine68$1,661
Paliperidone ErPaliperidone16$1,204
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine32$1,044
Prazosin Hcl42$967
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$802
Lamotrigine48$787
Duloxetine Hcl52$773
Trazodone Hcl57$657
Clonazepam105$647
Lurasidone Hcl19$524
Amitriptyline Hcl13$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$12$45,92915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 142 psychiatric/mental health providers in Montana.

Other psychiatric/mental health in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →